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Background: This study is conducted mainly to evaluate the changes in quality and quantity of oral epithelial cells 
during the course of IMRT. 
Material and Methods: 30 Patients undergoing chemo-radiotherapy were followed through course of treatment. 
They were compared with a group of age- and sex-matched healthy individuals. The procedure involved WHO 
clinical scoring, collection of oral washings and preparation of buccal smears from both study group and control 
group. The changes occurred were recorded as a way of assessing the severity of oral mucositis.
Results: revealed a significant occurrence of oral mucositis in almost all patients during weekly follow up. There 
was a significant increase in percentage of viable buccal epithelial cells in study group when compared to normal 
controls (P<0.005) during and at the end of chemo-radiotherapy. 
Conclusions: quantification of oral mucositis can be done at cellular level by determining the oral mucosal cell 
viability and their maturation during IMRT.
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Cytologic evaluation of irradiation effects on oral mu-
cosa was reported in 1957 and on oral cancer in 1959 
(1,2). Growing evidence indicates that more aggressive 
regimens improve local tumor control and survival of 
patients with head and neck cancer. These have come, 
however, at the expense of increased patient morbidity, 
notably an increase in severe mucositis that causes sub-
stantial pain, interferes with chewing, swallowing, and 
substantially worsens the patient’s quality of life (3).
Oral mucositis is a common, dose limiting and poten-
tially serious complication of both radiation and chemo-
therapy. These therapies are non-specific, interfering 
with the cellular homeostasis of both malignant and 
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normal host cells. An important effect is the loss of 
rapidly proliferating epithelial cells in the oral cavity. 
Within  the  mouth,  the  loss  of  these  cells  leads  to 
mucosal  atrophy,  necrosis  and ulceration (4).
Oral mucositis induced by irradiation is defined as a re-
active inflammatory-like process of the oral and oropha-
ryngeal mucous membranes. The severity of mucositis 
is determined by the radiation parameters of dose per 
day, cumulative dose, volume of irradiated tissue and 
type of ionizing radiation (5).
Mucositis induced by antineoplastic drugs is an im-
portant, dose limiting and costly side effect of cancer 
chemo-therapy (6). Direct toxicity to the oral epithelium 
is perhaps the most obvious drug induced cause. This 
usually occurs within 5 to 10 days post administration 
of medication. The drug induced neutropenia can mani-
fest as mucositis (Indirect toxicity). Microbial culturing 
and PCR analysis are critical at this point to differenti-
ate chemotherapy induced mucosal toxicity from mu-
cosal neutropenic infectious complications caused by 
bacterial, fungal or viral microorganisms (7).
Radio-chemotherapy regimens induce high levels of 
acute toxicity, significantly higher than for radiotherapy 
alone. The addition of chemotherapy introduces sys-
temic toxicity and can exacerbate local tissue reactions 
when used concurrently with radiotherapy. Mucositis 
is recognized as the principal limiting factor to further 
treatment intensification in such situations (8). As new 
agents become available and as combinations of radio-
therapy and multiple drug chemotherapy are used con-
currently, reports of apparent interaction are appearing 
frequently in the literature (9). Counting the percentage 
of viable oral epithelial cells in oral washings may be 
useful as an objective parameter in studies focused on 
mucositis prevention (10).
This study is aimed at quantification of oral  mucositis 
that develops during the Intensity Modulated Radiation 
Therapy (IMRT) at the cellular level by determining the 
viability of oral  mucosal  epithelial  cells and  com-
paring  them  with  clinical  World Health Organiza-
tion (WHO) grading through the period of therapy. The 
study also aims at proving the efficacy of this method in 
predicting mucositis at an earlier stage of IMRT when 
compared to the WHO clinical scoring which is being 
commonly used.
Material and Methods
Participants: 30 patients who are diagnosed as having 
Head and Neck malignancy including salivary glands 
and undergoing chemo-radiotherapy as treatment op-
tion were selected and followed up through the course 
of treatment. 
The control group consisted of age matched 30 normal 
healthy persons (16 male/ 14 female) who were systemi-
cally well and not under any medication or without any 
adverse habits. Exclusion criterias were: patients with 
any oral mucosal defect, patient who needs any obtu-
rator or prosthesis, treatment with antibiotics in the 2 
week period before the start of therapy, oral candidia-
sis or acute periodontitis and patients with naso-gastric 
tube at the start of treatment.
The procedure involves clinical scoring, collection of 
oral washings and preparation of buccal smear from 
both study group and control group. For the study group, 
clinical procedures were done on the first day prior to 
the commencement of therapy. Then the next samples 
were taken at 7th, 14th and 21st day. If the patient expe-
riences any complications, weekly samples will be col-
lected till the oral mucosa returns to normal. Only the 
initial single samples were collected for healthy controls 
as per the inclusion and exclusion criteria. Proper In-
stitutional Review Board (IRB) and Ethical committee 
approval were obtained from the Institutions before the 
start of the study. The patients also provided signed in-
formed consent before the collection of initial samples.
- I. Oral mucositis scoring: 
Patients who were to undergo chemoradiotherapy were 
clinically evaluated for mucositis and scoring will be 
done based on WHO scale. i.e. grade 0 - no change, 
grade 1 - soreness/ erythema, grade 2  - erythema/ ul-
cers/ can eat solids, grade 3 - ulcers/ requires liquid diet 
only, grade 4 - alimentation not possible (11). Buccal 
mucosa on the treated side and those regions of oral 
mucosae which were included in the Radiation Therapy 
(RT) target areas were included for the grading.
- II. Oral Washings: 
Patients were asked to rinse (or gargle if the RT site was 
located in the posterior regions of the oral cavity) their 
mouth with 10ml sterile saline for 15seconds and to spit 
into a glass beaker. This was centrifuged at 190g, 10 
minutes at room temperature (ACSW-163 centrifuge 
machine, Atul chemicals and scientific works) and the 
centrifugate cells were obtained. The cells are sus-
pended in 1ml of RPMI 1640 (Hi media Lab Pvt Ltd, 
Mumbai, India) medium containing fetal calf serum 
(Hi media Lab Pvt Ltd, Mumbai, India) 5% and the sus-
pension is divided into two parts. A micropipette (SC 
- single channel, Atul chemicals and scientific works) 
was used to obtain 50µl of suspension and was treated 
with 50µl  trypan blue (Hi media Lab Pvt Ltd, Mumbai, 
India) - 0.4%  and immediately transferred to haemocy-
tometer and cell count was performed. The other part 
was incubated for 15 minutes with acridine orange (Hi 
media Lab Pvt Ltd, Mumbai, India) and diluted with 
phosphate buffer saline and were examined by fluores-
cence microscopy. The percentage of apoptotic buccal 
epithelial cells was determined. Cells were scored as 
apoptotic when their nucleus showed condensation.
- III. Buccal smear: 
The buccal scrapings from representative sites (which 
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were included in the RT plan) were selected which were 
expected to develop oral mucositis during the course. 
The sites were scrapped, fixed using ether alcohol af-
ter preparing the smear and stained using Papanicolaou 
stain. Epithelial cell morphology and differentiation 
were studied under the light microscope. Cells were 
graded as follows:
• Orange stained cells - mature
• Blue/green stained cells - immature
• Partly orange and partly green - intermediate matura-
tion (12) 
Blood investigations reports were obtained from the pa-
tient records for the study group on the day of sample 
collection. Total count, differential counts were esti-
mated and level of blood leukocytes and oral leukocytes 
were tabulated. Results were statistically evaluated us-
ing “t test”, Wilkoxson signed rank test.
Results
The study group consisted of 30 persons who received 
chemo-radiotherapy by IMRT. The radiation doses re-
ceived by the fourth week are between 999 rads to 4200 
rads. The gender wise distribution consisted of 25 males 
(83%) and 5 females (17%). Major forms of carcinomas 
(CA) included were CA tongue (6 cases) followed by CA 
buccal mucosa (3), CA oropharynx (3) and CA tonsil (3) 
and also a case of mucoepidermoid carcinoma. Com-
parison of WHO mucositis grading from week 1 to 4 
showed that there was a significant increase in incidence 
and severity of oral mucositis starting from week 2. A 
severe form of mucositis development was observed by 
the end of fourth week. In week 3 mean frequency of 
patients exhibiting grade 2 mucositis increased slightly 
and none of the patients were under grade 0 anymore. 
As the patients entered week 4 considerable numbers of 
patient exhibited grade 3 type of mucositis. Statistics 
showed p-value (< 0.0005) between week 1 and 2, week 
1 and 3 and also week 1 and 4. The mean percentage 
viability between study and controls had a statistically 
insignificant difference. The test group showed statis-
tically similar percentage of viable cells (p- 0.191) at 
the beginning of therapy as compared to the normal 
controls. There was a statistically significant increase 
in percentage viable cells from week 1 to week 4 (95% 
Confidence Interval - 1.628, 3.279, 3.400 and 4.29 re-
spectively).
On comparing the cells of the buccal smears stained 
using PAP, there was an insignificant variation in the 
baseline difference between the mature cells of controls 
and week 1 sample of study group (p - 0.009) and a mild 
difference between intermediate cells (p - 0.013) of the 
study group and control while the percentage of imma-
ture cells (p - 0.805) was almost similar. Mature, in-
termediate and immature cells were compared in study 
group during treatment. A statistically significant (p - 
<0.0005) decrease in percentage of mature cells from 
week 1 to week 4 was observed and intermediate cells 
showed insignificant variations ( p - 0.129, 0.081 and 
0.243) for weeks 2, 3 and 4 respectively. Immature buc-
cal cells showed statistically significant (p < 0.0005) 
increase from week 1 to week 4. The WHO mucositis 
score corresponded with viable cell count and showed 
earlier change when compared to WHO grading. There 
was no statistically significant difference between pa-
tients who underwent only radiotherapy with IMRT and 
who underwent adjuvant chemo-radiotherapy (P-0.184) 
in percentage of viable cells.
Discussion
Complications associated with chemo-radiotherapy can 
be direct, caused by toxic action of treatment agents on 
the proliferative mucosal lining of the mouth or indirect, 
the result of hemopoeitic shut down (13).The earliest 
signs and symptoms of oral mucositis include erythema 
and edema, a burning sensation, and an increased sen-
sitivity to hot or spicy food. (14).The grade I to grade IV 
mucositis can be evaluated on clinical grounds (15,16).
In our  present study  the WHO  mucositis  clinical 
grading system; which was demonstrated to very effi-
ciently represent the clinical scale in accordance with a 
validated questionnaire was utilized (17). This showed 
that every patient  had a significant  increase  in the 
gradation  of mucositis  mostly  starting  from the 2nd 
week of treatment   and  by the  end  of the  4th    week, 
grade III or grade IV  mucositis. There  was a statisti-
cally  significant  difference  between  the clinical  grade 
of mucositis between week 1 and week 2. In order to 
overcome the disadvantages of clinical scoring system, 
we used the in vitro assay (10) that showed increase in 
viable oral epithelial cells which correlated with the 
increase in number of immature epithelial cells. This 
was believed to be due to an increased desquamation of 
the upper oral epithelial layers after high-dose chemo-
therapy.
The main reason for undertaking the study is to estimate 
whether the state of art IMRT has any advantage over 
conventional RT. In our study, approximately 63% of 
patients developed severe form of mucositis as per the 
WHO mucositis grading scale (Fig. 1). The mean per-
centage viability difference between pretreatment study 
and normal controls were (p-0.191). Increasing percent-
age of viable epithelial cells (Table 1) can be considered 
an earlier indicator of development of mucositis (10,18). 
The Confidence Interval (95%) compared from week 1, 
2, 3 and 4 (1.628, 3.279, 3.400, 4.29) did not exhibit any 
overlap evidencing the statistical significance of using 
viable cell percentage for predicting the mucositis de-
velopment (Table 2). 
In the present study of chemo-radiotherapy, the vi-
able  epithelial cell levels were compared  using the Pap 
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stained buccal smears by counting the percentage   of 
mature, intermediate and  immature cells. The study 
group and control group showed statistically insignifi-
cant differences in intermediate and immature cells 
(p-0.013, 0.805) whereas, a significant difference was 
observed in mature cells (p-0 .009) during the start 
of therapy. On progression of treatment; mature cells 
showed a statistically significant   p (<0.0005)   decrease 
starting from week 2 to week 4. While the  immature 
cells  showed  a significant  increase  from  week  2 to 
week 4, the  mean  difference being  6. 2, 9.9 and 13.4 
respectively. The intermediate type  of cells appeared 
to be in constant number  as can be observed  from  the 
p value  of 0.129,  0.081, 0.243 which  showed  statisti-
cally insignificant difference. The increase in percent-
age of immature cells corresponded to the increase in 
viable epithelial cells. This phenomenon   was  probably 
due  to  an increased  desquamation of the upper oral 
epithelial layer  after  high  dose  chemotherapy (10). 
Fig. 1. Frequency table comparing the incidence of oral mu-




week 2- week 1 
WHO mucositis 
week 3- week 1 
WHO mucositis 
week 4- week 1 
Z -4.873 -4.890 -4.928 
p-value <.0005 <.0005 <.0005 
Table 1. The Wilcoxon signed rank test comparing WHO mucositis grading. 
Group Week 1 Week 2 Week 3 Week 4 
ConfidenceInterval (95%) 1.628 3.279 3.400 4.289 
Lower limit 28.005 39.520 45.266 48.144 
Higher limit 31.261 46.079 52.067 56.723 
Table 2.  Confidence Interval (95%) of viable cells from week 1 to week 4.
Fig. 2. Comparison of mature, intermediate and immature buccal 
cells between week 1, week 2, week 3 and week 4 of study group.
The chemo-radiotherapy induced oral mucositis has 
been extensively evaluated in patients receiving Hemat-
opoietic Stem Cell transplantation (HSCT) and a study 
by Archibald et al. state that the addition of chemother-
apy to the treatment regimen did not increase the inci-
dence of complications when compared with historical 
controls receiving radiotherapy alone (19,20). Our study 
using IMRT also showed a similar pattern of behavior 
of upper epithelial cell layer (Fig. 2). Our study showed 
a shift from  mature  to  immature   cells (10) and  this 
proves  the  profound   effect  of  chemotherapy   on 
cells  when  compared   to  radiotherapy.  There was sta-
tistically no difference in this trend between the patients 
who underwent chemo-radiotherapy and radiotherapy 
alone (18). The findings also correlated well with the 
increased percentage of viable epithelial   cells as the 
chemo-radiotherapy   progressed. There was a signifi-
cant increase in viable cells as compared to the WHO 
score in second week which is also well evidenced by 
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increase in number of mature cells by the end of week 4 
(Fig.  2). The change in viability preceded the change in 
WHO score (Fig. 3).  This means that this assay is more 
sensitive for the detection of mucositis in adjunct to the 
clinical WHO toxicity grading system.
Fig. 3. Comparison of Viability percent and WHO score from 
week 1 to week 4 – shows viability. showing marked increase dur-
ing week 2 and earlier than WHO score as a better predictor of 
Oral mucositis occurrence.
In conclusion, after high-dose chemoradiotherapy, the 
percentage of viable oral epithelial cells increases.  Also, 
a shift from mature to immature cells in the buccal epi-
thelium is observed. This is possibly due to a desqua-
mation   of the upper oral epithelial layer. The specific 
target calculation during IMRT can reduce the total area 
of the oral mucosa affected due to chemo-radiotherapy 
but will not be significant. Newer treatment modalities 
can be considered that can counteract the side effects of 
chemotherapeutic agents. A larger clinical trial would 
be giving more accurate results in this regard. A de-
creased loco-regional control, poorer quality of life and 
shortened overall survival has been recently associated 
with unplanned treatment breaks and reduction in dose 
intensity (21). Therefore such assessment aids in mu-
cositis can become valuable in future. The in-vitro as-
say utilized may also be useful as an adjunct in studies 
focused on oral mucositis prevention.
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